Author: admin

Transformational Acquisitions Expected to Contribute to Long Term Growth Starting 2Q26

HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 1Q2026 and provides full year outlook.

1Q26 Business and Financial Highlights

• The Company reported 1Q26 revenues of NT$4,001 million, down 17.68% sequentially, with basic EPS of NT$0.21. Gross margin stabilized quarter-over-quarter. The quarter reflected temporary slowdown across both businesses: pricing and demand variability in the generics market through January and February left Upsher-Smith’s 1Q26 revenue 18.63% below the trailing four-quarter run rate, while the scheduled annual maintenance of 6 weeks of our Maryland fill-finish facility limited fixed-cost absorption during the quarter, weighed on earnings quality.
• March saw a rebound in both businesses as conditions improved for both the top and bottom lines with steady demand. During the quarter, the Company advanced Maple Grove site ramp-up significantly, with several multi-year CDMO agreements signed or progressing across pharma clients of various sizes. Additionally, the Company continues to win new CDMO business as 12-month rolling backlog arrived at US$315 million. With a healthy order book at North American sites entering the second quarter, we expect fixed-cost leverage to resume, driving profit improvement as utilization builds across the installed asset base. Meanwhile, Upsher-Smith has successfully defended market share and is deploying lifecycle management initiatives that reinforce our ability to set the cadence of sales in a dynamic competitive environment.
• Non-operating loss primarily reflected a wider equity loss from affiliate Tanvex Biopharma, together with higher tax expense driven by annual 1Q recognition of tax from undistributed earnings of the previous year.
• Disciplined OPEX control has driven expenses down 14.87% quarter-over-quarter and 14.41% year-over-year. This signals that resources have settled in as we begin to see advantages in scale; The Company expects ROA and ROIC to trend gradually upward, albeit with some quarter-to-quarter variability as operating leverage builds.
• Board of Directors approved the acquisition of the CDMO business of MacroGenics Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, leading to a total 12-month rolling backlog upon closing to approximately US$375 million.
• Sunway Biotech’s Board approved the 100% acquisition of Weider Global Nutrition (“WGN”), an iconic Phoenix-based American sports nutrition brand with a strategic Costco U.S. supplier relationship, commercial presence in 60+ countries, and established positions on Amazon and Walmart. The transaction completes Bora Group’s three-platform architecture, namely CDMO, pharma sales, and nutraceuticals operated under our “dual engine” strategy.
• Share capital increased 0.04% during the quarter from employee stock option exercise.

Mr. Bobby Sheng, Chairman of Bora Group, stated, “The beginning of 2026 was eventful and challenging both in the world and at Bora. We have seen supply chain disruptions, inflation from wars, and continuous geopolitical tensions. Yet through it all, Bora Group’s disciplined approach to growth-oriented investment remained unwavering.

Our CDMO business CAPEX-to-revenue ratio reached an all-time high of over 10% in 2025, marking another year of upward progression and bringing the Company to a level comparable with established global CDMO peers. This marked a deliberate shift in where we direct investments from capacity-led expansion that defined our earlier growth chapters to a sharper focus on capability demands and modality, anchored in innovation and technology. Over the past 18 months, we have pursued an ambitious growth trajectory against a dynamic macroeconomic backdrop – recalibrating expectations, sharpening our strategy, and reaffirming long-term plans. The underlying demand environment supports our conviction: global pharma is growing at 5-8% per year, biologics CDMO outsourcing demand at 15%+ and small-molecule outsourcing demand at 8-10%. With our investment foundation now in place, we believe our CDMO business is positioned to compound organically at 13-23% annually.

In the first quarter, we executed a series of organizational adjustments, each aligned to a specific dimension of customer demand. We established the MSAT (Manufacturing, Science and Technology) function within the CDMO business, the R&D backbone of the platform, to deepen scientific and technical capability across our entire client base, an increasingly critical asset as small and mid-sized biotech and pharma clients rethink their supply chain. In parallel, we repurposed the Strategic Enterprise Account Management team into a networked model to serve clients for whom customer proximity is paramount. Together, these capability investments target specific customer pain points and position Bora to navigate the evolving political and economic landscape and capture a new chapter of commercial momentum.

To sum up, CDMO business in 1Q26 delivered US$27.2 million in total external wins on top of orders on hand, 60% or 7 molecules from pre-commercial programs. For context, full-year 2025 saw 16 pre-commercial molecule signings; 1Q26 alone has already secured nearly half that count in a single quarter. This run-rate acceleration is a leading indicator: as our capability investments take hold, forward visibility and growth potential are set to compound. Bora’s CDMO business has entered a new phase. Reinforcing this trajectory, the Group’s recently announced acquisition of MacroGenics’ Rockville, Maryland CDMO facility adds a substantial commercial-stage monoclonal antibody programs backlog and manufacturing expertise to the Group. Equipped with five 2,000-liter and two 500-liter single-use bioreactors and integrated QC and analytical labs and currently generating more than half of revenues from commercial manufacturing, the transaction marks a pivotal step in scaling Bora’s integrated biologics CDMO platform, known as Bora Biologics. DS and DP capabilities shall be integrated over the next 12–18 months to offer global biotech customers a single partner from development through commercial supply in the U.S..

On the pharma sales side, the Group faced competition across a handful of core generic products. Upsher-Smith is navigating the competitive landscape with a clear focus on the most margin-accretive opportunities while continuing to scout niche, brand-oriented assets. Near-term, DLS market share has been defended; over the medium term, sustained market share maximization of the infantile spasm franchise coupled with swift pipeline replenishment weighted toward differentiated assets is critical. In the first quarter, we saw unique patients for VIGAFYDE grew by more than 140% over same period last year and a continuous increase in new patients. Both healthy signs of steady execution pace building up to durable resilience in the pharma sales business.”

1Q26 Operational Achievements & 2026 Outlook

Global CDMO Operations

Revenues declined 24.62% year-over-year and 30.15% quarter-over-quarter including internal orders, mainly due to above-mentioned maintenance at fill and finish facility in Maryland, a routine cycle factored into our operating plan, and seasonality at Canada site. To scale biologics CDMO one-stop-shop platform in commercialized projects with SUB (Single Use Bioreactors) in the US; Board of Directors approved the acquisition of Rockville, Maryland based drug substance facility from MacroGenics for US$122.5 million.

Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to expand and strengthen the Group’s end-to-end biologics platform. The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA.

During the quarter, 0.44 billion doses, or 108 molecules, were developed and manufactured. Excluding internal orders, the business accounted for 37.73% of consolidated revenues. Contribution from the top 20 global pharmaceutical companies stood at 32.10%.

As the Company continues to expand its CDMO capacity and capabilities, this year’s CAPEX plan is closely linked to the contracting cadence of a key customer anchored at Bora’s North American CDMO network. The Group expects to complete Maple Grove’s capital expenditure program in the first half of the year, sequencing the investment to grow in step with major pharmaceutical partners’ supply chain plans and optimize return on capital deployed.

Pharma Sales Operations

Discontinued operations impact in 2025 has materially abated this quarter, positioning Upsher-Smith to re-accelerate organic growth in 2026. Management has defined two strategic priorities for 2026, designed to enhance capital efficiency and sharpen commercial focus:

First, R&D capital allocation optimization. 505(b)(2) Pipeline programs have been transferred to Salus Therapeutics, an equity-method affiliate. Under this structure, Upsher-Smith retains the right to economic participation in commercial outcomes while shareholders’ exposure to early-stage development and regulatory risks, and associated cash burden is meaningfully reduced. The decision is consistent with the Group’s capital discipline observed across businesses.

Second, institutionalizing pipeline expansion capabilities. An integrated business development and medical affairs function is being established to systematically evaluate in-licensing, co-promotion, and bolt-on opportunities. This integrates Bora’s proven asset-selection and M&A strategy directly into Upsher-Smith’s commercial infrastructure, enabling franchise compounding through targeted external sourcing rather than capital-intensive internal development. These lifecycle initiatives focus but are not limited to pediatric epilepsy opportunities.

Collectively, Management expects Upsher-Smith to evolve fully into a capital efficient, commercially led, and therapeutically centered vehicle designed to deliver sustained shareholder value before exiting 2026.

Recent Investor Conference

Bora will host English online earnings call at 7:30 a.m. Taiwan time on May. 14^th, 2026. The event will cover the Company’s 1Q26 financial and business results and 2026 outlook.

English Online Earnings Presentation Link: https://events.q4inc.com/attendee/372103448

Bora will participate in 2026 Yuanta Securities Investment Forum in June. For 1:1 meetings with management, please contact your Yuanta representative.

Bora 2026 Earnings Schedule

Q2 2026: Expected in the 2^nd week of Aug 2026
Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

以《大龍鳳》為劇場 IP 案例，連接粉絲參與與娛樂資產代幣化應用，潛在項目儲備規模預計逾港幣20億元

香港 – Media OutReach Newswire – 2026年5月13日 – 毅盛金融科技（證券）有限公司（「Esperanza」或「公司」）欣然宣布，旗下管理的代幣化基金參與協辦天下一幕有限公司（「天下一幕」）旗下的香港本地劇場 IP 項目《大龍鳳》，雙方已就此簽署合作安排。天下一幕為天下一集團旗下子公司。是次合作標誌著 Esperanza 繼早前娛樂演出代幣化項目後，進一步將其合規金融科技方案延伸至香港劇場、文化 IP 及粉絲參與場景，持續探索文化娛樂資產於新金融模式下的商業價值與應用潛力。

天下一集團為香港具代表性的綜合影視娛樂企業，業務涵蓋電影、電視、製作、後期製作、藝人管理及相關娛樂產業服務。是次與天下一幕的合作，不僅反映 Esperanza 持續拓展文化娛樂資產代幣化應用場景，亦展示香港本地優質內容及 IP 項目在新金融模式下的更多發展可能。

作為立足香港、面向亞太的金融科技及真實世界資產代幣化平台，Esperanza 致力於在合規框架下，連接優質資產、合資格投資者、內容持有人、項目營運方及粉絲社群，為文化娛樂項目建立更具透明度、參與度及延展性的金融基礎設施。

Esperanza 集團行政總裁兼首席法務官梁衞晉表示：

「《大龍鳳》項目不單是一個劇場合作，更是 Esperanza 在香港文化娛樂資產金融化領域的另一個重要實踐案例。香港一直是亞洲文化、創意及金融交匯的重要城市，我們希望以香港作為起點，將本地優質文化娛樂內容與新型金融科技工具結合，推動內容持有人、項目方、粉絲社群及合資格投資者之間形成更深層次的價值連結。在本項目中，Esperanza 亦將於香港率先推出代幣化體驗應用，讓支持者可透過相關代幣化安排，參與門票兌換、專屬周邊及文化娛樂體驗消費，進一步延伸舞台作品與觀眾之間的互動關係。透過合規代幣化方案，Esperanza 將持續協助更多具文化價值及市場潛力的項目，建立更靈活、更透明及更具參與感的新金融連接模式。」

天下一集團首席財務官黃詠茵表示：

「我們很高興能與 Esperanza 團隊展開合作。在現今多元化的娛樂產業生態中，財務架構的創新對於推動創意產業發展至關重要。透過這次合作，我們期待能運用專業的金融科技工具方案，為香港文化娛樂資產開拓更靈活的商業可能。」

是次合作亦反映 Esperanza 在娛樂及文化資產領域的持續布局。公司正積極發掘更多具備代幣化潛力及商業延展性的項目，涵蓋電影、現場娛樂、劇場 IP、授權業務、AI 沉浸式娛樂、多媒體應用、體驗式場景，以及其他具備真實資產基礎及商業現金流潛力的項目類別。

Esperanza 預期，隨著亞太區內容產業、粉絲參與模式、人工智能技術及沉浸式娛樂生態快速發展，市場將需要更成熟的合規金融平台，協助優質文化娛樂項目拓展資本連接、社群參與及商業化能力。目前，公司正評估及推進多個相關項目，潛在項目儲備規模預計逾港幣20億元，涵蓋娛樂文化、授權 IP、物業、多媒體、AI 沉浸式娛樂及其他真實世界資產應用方向。

Esperanza 強調，公司將繼續以合規、透明及可持續發展為核心，推動文化娛樂資產由傳統項目融資及單一消費模式，逐步走向更制度化、數碼化及具參與性的新金融市場模式，為香港及亞太區創意產業創造新的增長空間。

Hashtag: #Esperanza

The issuer is solely responsible for the content of this announcement.

關於毅盛金融科技（證券）有限公司

毅盛金融科技（證券）有限公司（「Esperanza」或「公司」）證券為一家根據證券及期貨條例（香港法例第571章）獲發牌的公司，獲許可進行第四類（就證券提供意見）及第九類（提供資產管理）業務。Esperanza 於2026年2月13日獲香港證監會確認對Esperanza 就其管理的基金進行代幣化一事並無進一步意見，即正式准許Esperanza 進行證券代幣化業務。

關於天下一幕有限公司

天下一幕有限公司（「天下一幕」）為天下一集團旗下公司，參與香港文化娛樂及劇場項目發展。 天下一集團成立於2013年，總部設於香港，是一家致力於電影與娛樂產業發展的綜合企業。本著「創新視野‧敢作敢為」的宗旨，集團建立橫跨整個娛樂產業價值鏈的多元業務版圖，並於亞洲主要市場建立穩定合作及業務布局。欲了解更多資訊，請瀏覽官網 www.onecool.com。

關於Esperanza金融科技集團

Esperanza金融科技集團是一家以香港為總部的金融科技公司。集團持牌業務包括 (i) 營運黃金交易及代幣化黃金的毅盛金融科技（商品）有限公司（一家於香港海關註冊的貴金屬交易商，核准註冊業務包括於www.espetopia.com進行發行、贖回及交易黃金支持工具。海關註冊編號A-B-25-03-08913）; (ii) 營運託管客戶資產的毅盛金融科技（代理人）有限公司（一家獲香港信託及公司服務提供者註冊辦事處發牌的信託及公司服務提供者，獲發牌業務包括向客戶提供資產託管服務。發牌編號TC010260）；(iii) 研發及營運espetopia.com交易平台系統的Espetopia Limited; 及關連公司 (iv) 毅盛金融科技（證券）有限公司, 一家獲香港證監會准許進行證券代幣化業務的公司。

以《大龙凤》为剧场 IP 案例，连接粉丝参与与娱乐资产代币化应用，潜在项目储备规模预计逾港币20亿元

香港 – Media OutReach Newswire – 2026年5月13日 – 毅盛金融科技（证券）有限公司（「Esperanza」或「公司」）欣然宣布，旗下管理的代币化基金参与协办天下一幕有限公司（「天下一幕」）旗下的香港本地剧场 IP 项目《大龙凤》，双方已就此签署合作安排。 天下一幕为天下一集团旗下子公司。 是次合作标志着Esperanza继早前娱乐演出代币化项目后，进一步将其合规金融科技方案延伸至香港剧场、文化IP及粉丝参与场景，持续探索文化娱乐资产于新金融模式下的商业价值与应用潜力。

天下一集团为香港具代表性的综合影视娱乐企业，业务涵盖电影、电视、制作、后期制作、艺人管理及相关娱乐产业服务。 是次与天下一幕的合作，不仅反映Esperanza持续拓展文化娱乐资产代币化应用场景，亦展示香港本地优质内容及IP项目在新金融模式下的更多发展可能。

作为立足香港、面向亚太的金融科技及真实世界资产代币化平台，Esperanza致力于在合规框架下，连接优质资产、合资格投资者、内容持有人、项目营运方及粉丝社群，为文化娱乐项目建立更具透明度、参与度及延展性的金融基础设施。

Esperanza 集团行政总裁兼首席法务官梁卫晋表示：

「《大龙凤》项目不单是一个剧场合作，更是 Esperanza 在香港文化娱乐资产金融化领域的另一个重要实践案例。 香港一直是亚洲文化、创意及金融交汇的重要城市，我们希望以香港作为起点，将本地优质文化娱乐内容与新型金融科技工具结合，推动内容持有人、项目方、粉丝社群及合资格投资者之间形成更深层次的价值连结。 在本项目中，Esperanza亦将于香港率先推出代币化体验应用，让支持者可透过相关代币化安排，参与门票兑换、专属周边及文化娱乐体验消费，进一步延伸舞台作品与观众之间的互动关系。 透过合规代币化方案，Esperanza将持续协助更多具文化价值及市场潜力的项目，建立更灵活、更透明及更具参与感的新金融连接模式。」

天下一集团首席财务官黄詠茵表示：

「我们很高兴能与 Esperanza 团队展开合作。 在现今多元化的娱乐产业生态中，财务架构的创新对于推动创意产业发展至关重要。 透过这次合作，我们期待能运用专业的金融科技工具方案，为香港文化娱乐资产开拓更灵活的商业可能。」

是次合作亦反映Esperanza在娱乐及文化资产领域的持续布局。 公司正积极发掘更多具备代币化潜力及商业延展性的项目，涵盖电影、现场娱乐、剧场IP、授权业务、AI沉浸式娱乐、多媒体应用、体验式场景，以及其他具备真实资产基础及商业现金流潜力的项目类别。

Esperanza预期，随着亚太区内容产业、粉丝参与模式、人工智能技术及沉浸式娱乐生态快速发展，市场将需要更成熟的合规金融平台，协助优质文化娱乐项目拓展资本连接、社群参与及商业化能力。 目前，公司正评估及推进多个相关项目，潜在项目储备规模预计逾港币20亿元，涵盖娱乐文化、授权IP、物业、多媒体、AI沉浸式娱乐及其他真实世界资产应用方向。

Esperanza强调，公司将继续以合规、透明及可持续发展为核心，推动文化娱乐资产由传统项目融资及单一消费模式，逐步走向更制度化、数字化及具参与性的新金融市场模式，为香港及亚太区创意产业创造新的增长空间。

Hashtag: #Esperanza

The issuer is solely responsible for the content of this announcement.

关于毅盛金融科技（证券）有限公司

毅盛金融科技（证券）有限公司（「Esperanza」或「公司」）证券为一家根据证券及期货条例（香港法例第571章）获发牌的公司，获许可进行第四类（就证券提供意见）及第九类（提供资产管理）业务。 Esperanza 于2026年2月13日获香港证监会确认对Esperanza 就其管理的基金进行代币化一事并无进一步意见，即正式准许Esperanza 进行证券代币化业务。

关于天下一幕有限公司

天下一幕有限公司（「天下一幕」）为天下一集团旗下公司，参与香港文化娱乐及剧场项目发展。 天下一集团成立于2013年，总部设于香港，是一家致力于电影与娱乐产业发展的综合企业。 本着「创新视野‧敢作敢为」的宗旨，集团建立横跨整个娱乐产业价值链的多元业务版图，并于亚洲主要市场建立稳定合作及业务布局。 欲了解更多信息，请浏览官网 www.onecool.com。

关于Esperanza金融科技集团

Esperanza金融科技集团是一家以香港为总部的金融科技公司。 集团持牌业务包括（i）营运黄金交易及代币化黄金的毅盛金融科技（商品）有限公司（一家于香港海关注册的贵金属交易商，核准注册业务包括于 www.espetopia.com 进行发行、赎回及交易黄金支持工具。 海关注册编号A-B-25-03-08913）; （ii） 营运托管客户资产的毅盛金融科技（代理人）有限公司（一家获香港信托及公司服务提供商注册办事处发牌的信托及公司服务提供商，获发牌业务包括向客户提供资产托管服务。 发牌编号TC010260）; （iii） 研发及营运 espetopia.com 交易平台系统的espetopia Limited; 及关连公司 （iv） 毅盛金融科技（证券）有限公司， 一家获香港证监会准许进行证券代币化业务的公司。

BANGKOK, THAILAND – Media OutReach Newswire – 13 May 2026 – LGT continues to strengthen its leadership team in Thailand with the appointment of Anchalee Bunsongsikul as Chief Executive Officer of LGT Securities (Thailand) Limited (“LGT Thailand”). This senior management hire underlines the strategic importance of Thailand for LGT and reflects the firm’s commitment to further expanding its presence in the market.

With over three decades of leadership experience in international banking, including most recently as President and Chief Executive Officer, Thailand and Representative Offices for Standard Chartered Bank, Anchalee Bunsongsikul will further strengthen LGT’s senior management bench in Thailand. She brings extensive experience in corporate banking, financial markets and client coverage, as well as a deep understanding of the local client landscape.

Commenting on the appointment, Dr. Henri Leimer, Chief Executive Officer, LGT Private Banking Asia Pacific, said: “Thailand is an important market for us, one where we have built a strong market position through a consistent, relationship-led approach focused on serving Thai families and entrepreneurs.” Karn Karuhadej, Managing Director and Senior Market Adviser, added: “Anchalee brings extensive leadership experience, strong client relationships and deep market knowledge that will further strengthen our franchise in Thailand. We look forward to welcoming her to our team and working together to further develop our business in the region.”

The appointment will take effect on 15 May 2026. Upon joining LGT Thailand, Anchalee Bunsongsikul will also become a member of the Executive Board Asia Pacific of LGT Private Banking.

LGT has deep roots in Asia. Since opening its first representative office in Hong Kong in 1986, LGT has grown into a competitive regional private bank and wealth manager. In 2019, LGT launched its wealth management business in Thailand. Today, the Bangkok office comprises a strong team of experienced relationship managers and investment consultants who provide investment and wealth management services to Thai clients, complementing LGT’s private banking operations in Hong Kong and Singapore.

Across Asia Pacific, LGT has a presence in Hong Kong, Singapore, Thailand, Japan, Australia, India and the Middle East, and employs around 1800 people in the region. In 2025, LGT ranked as the sixth¹ largest private bank in the region, with USD 164 billion in assets under management as of the end of 2025.

Hashtag: #LGT

The issuer is solely responsible for the content of this announcement.

LGT in brief

LGT is a leading international private banking and asset management group that has been fully controlled by the Liechtenstein Princely Family for over 90 years. As at 31 December 2025, LGT managed assets of CHF 386.1 billion (USD 487.3 billion) for wealthy private individuals and institutional clients. LGT employs 6000 people who work out of more than 40 locations in Europe, Asia, the Americas, Australia and the Middle East. www.lgt.com.

Hong Kong theatre IP “The Big Big Day” anchors the next phase of fan participation and entertainment asset tokenization, with qualifying projects potential exceeding HK$2 billion in scale

HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Esperanza Fintech (Securities) Limited (“Esperanza” or the “Company“) is pleased to announce that a tokenized fund managed by the Company has participated in co-presenting The Big Big Day (《大龍鳳》), a Hong Kong theatre IP project produced by One Cool Stage Limited (“One Cool Stage“), a subsidiary of One Cool Group Limited. A cooperation arrangement to this effect has been signed by both parties. The collaboration marks a further extension of Esperanza’s regulated fintech solutions — building on its earlier tokenized live-entertainment offerings — into Hong Kong theatre, cultural IP, and fan-engagement scenarios, as the Company continues to explore the commercial value and applications of cultural and entertainment assets under new financing models.

One Cool Group Limited is one of Hong Kong’s most recognizable integrated film and entertainment enterprises, with operations spanning film, television, production, post-production, artist management, and related entertainment services. The partnership with One Cool Stage not only reflects Esperanza’s continued expansion of tokenization use cases for cultural and entertainment assets, but also showcases the broader development potential of high-quality Hong Kong content and IP under new financing frameworks.

As a Hong Kong-based fintech and real-world asset (RWA) tokenization platform serving the Asia-Pacific market, Esperanza is committed to operating within a regulated framework to connect quality assets, professional investors, content owners, project operators, and fan communities — building more transparent, participative, and scalable financial infrastructure for cultural and entertainment projects.

Mr. Ronald Leung, Group Chief Executive Officer and Chief Legal Officer of Esperanza, said:

“The Big Big Day project is more than a single theatre collaboration — it represents another important milestone in Esperanza’s work to bring tokenized capital solutions to Hong Kong’s cultural and entertainment assets. Hong Kong has long stood at the intersection of Asian culture, creativity, and capital. We see this city as the ideal starting point for combining high-quality local content with next-generation fintech infrastructure, and for forging deeper value linkages among content owners, project parties, fan communities, and professional investors. As part of this project, Esperanza will also take the lead in launching tokenized experience applications in Hong Kong, enabling supporters to participate in ticket redemption, exclusive merchandise offerings, and cultural entertainment experiences through relevant tokenized arrangements. This will further extend the interaction between stage productions and audiences beyond the performance itself. Through compliant tokenization solutions, Esperanza will continue to support more projects of cultural significance and market potential in establishing financing connections that are more flexible, more transparent, and more participatory.”

Ms. Ella Wong, Chief Financial Officer of One Cool Group Limited, said:

“We are delighted to begin this collaboration with Esperanza. In today’s diversified entertainment ecosystem, innovation in financial structuring is critical to advancing the creative industries. Through this partnership, we look forward to leveraging professional fintech infrastructure and solutions to open up more flexible commercial possibilities for Hong Kong’s cultural and entertainment assets.”

This collaboration also reflects Esperanza’s continued strategic build-out in entertainment and cultural assets. The Company is actively sourcing additional projects with tokenization potential and commercial scalability — across film, live entertainment, theatre IP, licensing businesses, AI-driven immersive entertainment, multimedia applications, experiential venues, and other categories underpinned by real-asset foundations and commercial cash flow potential.

As Asia-Pacific’s content industries, fan-engagement models, AI technologies, and immersive entertainment ecosystems continue to evolve rapidly, Esperanza expects growing market demand for mature, compliant financial platforms capable of helping high-quality cultural and entertainment projects expand their access to capital, community engagement, and commercialization capabilities. The Company is currently evaluating and progressing multiple related opportunities, with a potential project pipeline expected to exceed HK$2 billion in scale across entertainment and culture, IP licensing, real estate, multimedia, AI immersive entertainment, and other real-world asset applications.

Esperanza emphasizes that the Company will continue to anchor its work in compliance, transparency, and sustainability — guiding cultural and entertainment assets from traditional project financing and single-consumption models toward more institutionalized, digitalized, and participatory new financing markets, and creating new growth opportunities for Hong Kong and the wider Asia-Pacific creative industries.

Hashtag: #Esperanza

The issuer is solely responsible for the content of this announcement.

About Esperanza Fintech (Securities) Limited

Esperanza Fintech (Securities) Limited (“Esperanza“) is a licensed corporation under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), permitted to carry on Type 4 (advising on securities) and Type 9 (asset management) regulated activities. On 13 February 2026, Esperanza received a “no further comment” letter from the Hong Kong Securities and Futures Commission in respect of its proposal to tokenize managed funds — formally permitting Esperanza to conduct tokenized investment business.

About One Cool Stage Limited

One Cool Stage Limited (“One Cool Stage“) is a subsidiary of One Cool Group Limited, engaged in the development of cultural, entertainment, and theatre projects in Hong Kong. Founded in 2013 and headquartered in Hong Kong, One Cool Group Limited is a diversified enterprise dedicated to the development of the film and entertainment industry. Guided by the philosophy of “Visionary in Creativity, Strive for Diversity,” the Group has built a multi-faceted business portfolio spanning the entire entertainment industry value chain, with stable partnerships and operational footprints across major Asian markets. For more information, please visit www.onecool.com.

About Esperanza Fintech Group

Esperanza Fintech Group is a fintech group headquartered in Hong Kong. The group’s licensed businesses include (i) gold trading and tokenized gold services operated by Esperanza Fintech (Commodities) Limited, a DPMS (dealers in precious metals and stones) Category A Registrant (No. A-B-25-03-08913) with the Hong Kong Customs with permitted businesses including the issuance, redemption and trading of gold backed instruments on www.espetopia.com; (ii) client asset custodian service operated by Esperanza Fintech (Nominees) Limited, a licensed Trust or Company Service Provider in Hong Kong (Licence No. TC010260), regulated by the Hong Kong Companies Registry; (iii) espetopia trading platform operated by Espetopia Limited; and (iv) tokenized investment services operated by affiliate company Esperanza Fintech (Securities) Limited, an SFC-regulated asset manager with permission to carry out tokenized investment businesses.

澳門特別行政區 – Media OutReach Newswire – 2026年5月12日 -「澳門銀河」隆重宣布正式啓動「『澳門銀河』高爾夫球大使計劃」，並與多位具備國際影響力的高爾夫球界精英達成合作協議，邀請來自中國香港的美國女子職業高爾夫球巡迴賽球手陳芷澄、知名藝人李思雅，聯同14位中國內地女子高爾夫球手，包括劉文博、石昱莉、楊曼莉香、張芸傑、何陳昊、林冶舟、楊嘉欣、黃芷瑩、趙依妮、王嫣、孟霖、洪婕寧、牛姿驊及黃逸懿出任「『澳門銀河』高爾夫球大使」。

是次委任國際級高爾夫球大使，為「澳門銀河」品牌發展注入嶄新動能，並進一步鞏固其在精緻生活、國際體育及休閒旅遊領域的定位。透過高爾夫運動作為連結平台，融合體育、文化、旅遊與生活品味，「澳門銀河」積極回應澳門經濟適度多元及打造世界旅遊休閒中心的發展方向，將專注、紀律與優雅的運動精神轉化為更具深度與層次的旅遊體驗，吸引全球賓客。

為實踐上述理念，「澳門銀河」於 5 月 8 日至 9 日成功舉辦「『澳門銀河』高爾夫球挑戰賽」，作為是次委任後的首場活動。比賽匯聚多位女子職業高爾夫球手同場競技，並邀得影視紅星王敏德及李思雅親臨現場揮桿助陣，將專業體育競技與時尚生活方式巧妙結合，成為「澳門銀河」推動高爾夫球運動及體育旅遊發展的重要里程碑。

陳芷澄自 2016 年展開全職球手生涯，是香港高爾夫球界於國際舞台上備受矚目的代表人物，曾以業餘身份於職業賽事奪冠，並代表中國香港出戰 2020 東京奧運會，以穩健球風與堅毅精神詮釋追求卓越的運動價值。

高爾夫球大使於賽場內外所展現的堅毅精神、持續突破的態度，與「澳門銀河」追求卓越體驗與高品質生活方式的核心理念高度契合。展望未來，「澳門銀河」將持續支持甚至舉辦更多高爾夫相關活動，攜手各界推廣體育旅遊及健康生活模式。同時支持中國高爾夫球運動發展，拓展運動文化的影響力，為中國內地及澳門特區社會及旅遊產業創造更具深度與可持續性的長遠價值。

有關「澳門銀河」及是次推廣的最新消息，敬請造訪：www.galaxymacau.com。

Hashtag: #澳門銀河

The issuer is solely responsible for the content of this announcement.

有關 「澳門銀河」 綜合度假城

「澳門銀河」世界級奢華綜合度假城打造全世界最多元化的娛樂及綜合旅遊度假熱點。整個項目的總投資額高達430億港元，佔地110萬平方米，為澳門帶來嶄新的休閒娛樂設施。 「澳門銀河」雲集9家世界知名豪華酒店，包括澳門悦榕庄、「銀河酒店」、澳門大倉酒店、澳門JW萬豪酒店、澳門麗思卡爾頓酒店、「百老匯酒店」、澳門銀河 萊佛士、澳門安達仕酒店，以及澳門銀河 嘉佩樂，共提供約5,000 間豪華客房、奢華套房及別墅。天浪淘園佔地75,000平方米，設有全球最長 575 米空中激流、能掀起1.5米人造海浪的空中衝浪池、全150米的白沙灘，以及澳門首個高達9米的刺激滑水天梯衝天激流。兩間五星級國際水療品牌─澳門悦榕SPA和澳門麗思卡爾頓水療中心讓賓客煥發心靈、徹底放鬆。

「澳門銀河」其他設施包括超過120個餐飲選擇，涵蓋米芝蓮星級體驗及地道美食，以多元風味、獨特體驗及頂級食材打造「舌尖品亞洲 峰味聚銀河」的餐飲享受。銀河時尚匯集合國際頂尖奢華品牌，禮遇非凡的悅心購物體驗，讓賓客一步到位選購全球追捧的經典及限量版名品，探索充滿驚喜亮點的名牌獨家限時店，享受尊尚的禮遇回饋及優惠購物賞。成為VIP更可尊享貼心的禮賓購物服務，獲邀參與專屬的大牌聯乘活動，奢華禮遇提升至全新層次。矚目的時尚喜悦，在此一觸即發，令賓客變成潮流焦點所在。

「銀河影院」配備最頂尖的影音科技、超豪華舒適的配套，以及細心周到的服務，將身臨其境的影院體驗提升到全新境界；以上海流金歲月為設計靈感的頂級娛樂聖殿【紅伶】，在華麗典雅的氛圍下呈獻醉人娛樂表演；悠然自足以傳統手法帶領賓客領略養生奧秘恢復活力。從「澳門銀河」穿過設有空調的行人天橋，90秒即可直達「澳門百老匯」，零距離體驗最地道的澳門特色及亞洲魅力。百老匯美食街搜羅了 35 種澳門及亞洲地道特色美食，從街頭小吃至老字號餐廳，每家店的招牌名菜都令人難忘。設有約2,500個座位的百老匯舞台匯聚世界級表演盛事。

「澳門銀河」備有獨特完善的活動場地，專業的服務團隊為賓客籌辦不同類型的會議展覽活動。銀河國際會議中心（GICC）為澳門會展業開啓新篇章，同時拓展集團在澳門的度假城版圖。其會展空間總面積達40,000平方米，並設有16,000座位、全澳最大的室内綜藝館——銀河綜藝館。

詳情請瀏覽：www.galaxymacau.com, www.broadwaymacau.com.mo及www.galaxyicc.com。

澳门特别行政区 – Media OutReach Newswire – 2026年5月12日 -「澳門銀河」隆重宣布正式启动”『澳門銀河』高尔夫球大使计划”，并与多位具备国际影响力的高尔夫球界精英达成合作协议，邀请来自中国香港的美国女子职业高尔夫球巡回赛球手陈芷澄、知名艺人李思雅，联同 14 位中国内地女子高尔夫球手，包括刘文博、石昱莉、杨曼莉香、张芸杰、何陈昊、林冶舟、杨嘉欣、黄芷莹、赵依妮、王嫣、孟霖、洪婕宁、牛姿骅及黄逸懿出任”『澳門銀河』高尔夫球大使”。

是次委任国际级高尔夫球大使，为「澳門銀河」品牌发展注入崭新动能，并进一步巩固其在精致生活、国际体育及休闲旅游领域的定位。透过高尔夫运动作为连结平台，融合体育、文化、旅游与生活品味，「澳門銀河」积极响应澳门经济适度多元及打造世界旅游休闲中心的发展方向，将专注、纪律与优雅的运动精神转化为更具深度与层次的旅游体验，吸引全球宾客。

为实践上述理念，「澳門銀河」于 5 月 8 日至 9 日成功举办”『澳門銀河』高尔夫球挑战赛”，作为是次委任后的首场活动。比赛汇聚多位女子职业高尔夫球手同场竞技，并邀得影视红星王敏德及李思雅亲临现场挥杆助阵，将专业体育竞技与时尚生活方式巧妙结合，成为「澳門銀河」推动高尔夫球运动及体育旅游发展的重要里程碑。

陈芷澄自 2016 年展开全职球手生涯，是中国香港高尔夫球界于国际舞台上备受瞩目的代表人物，曾以业余身份于职业赛事夺冠，并代表中国香港出战 2020 东京奥运会，以稳健球风与坚毅精神诠释追求卓越的运动价值。

高尔夫球大使于赛场内外所展现的坚毅精神、持续突破的态度，与「澳門銀河」追求卓越体验与高质量生活方式的核心理念高度契合。展望未来，「澳門銀河」将持续支持甚至举办更多高尔夫相关活动，携手各界推广体育旅游及健康生活模式。同时支持中国高尔夫球运动发展，拓展运动文化的影响力，为中国内地及澳门特区社会及旅游产业创造更具深度与可持续性的长远价值。

有关「澳門銀河」及是次推广的最新消息，敬请造访：www.galaxyresorts.com.cn。

Hashtag: #澳門銀河

The issuer is solely responsible for the content of this announcement.

有关「澳門銀河」综合度假城

「澳門銀河」综合度假城打造全世界最多元化的娱乐及综合旅游度假热点。整个项目的总投资额高达430亿港元，占地110万平方米，为澳门带来崭新的休闲娱乐设施。「澳門銀河」云集九家世界知名豪华酒店，包括澳门悦榕庄、「銀河酒店」、澳门大仓酒店、澳门银河 JW万豪酒店、澳门银河 丽思卡尔顿酒店、「百老汇酒店」、澳门银河 莱佛士、澳门安达仕酒店，以及澳门银河 嘉佩乐，共提供约5,000间豪华客房、奢华套房及别墅。天浪淘园占地75,000平方米，设有全球最长575米空中激流、能掀起1.5米人造海浪的空中冲浪池、全长150米的白沙滩，以及澳门首个高达9米的刺激滑水天梯冲天激流。两间五星级国际水疗品牌——澳门悦榕SPA和澳门丽思卡尔顿水疗中心让宾客焕发心灵、彻底放松。

「澳門銀河」其他设施包括超过120个餐饮选择，涵盖米芝莲星级体验及地道美食，以多元风味、独特体验及顶级食材打造「舌尖品亚洲 峰味聚银河」的餐饮体验。银河时尚汇集合国际顶尖奢华品牌，礼遇非凡的悦心购物体验，让宾客一步到位选购全球追捧的经典及限量版名品，探索充满惊喜亮点的名牌独家限时店，享受尊尚的礼遇回馈及优惠购物赏。成为VIP更可尊享贴心的礼宾购物服务，获邀参与专属的大牌联乘活动，奢华礼遇提升至全新层次。瞩目的时尚喜悦，在此一触即发，令宾客变成潮流焦点所在。

「银河影院」配备最顶尖的影音科技、超豪华舒适的配套，以及细心周到的服务，将身临其境的影院体验提升到全新境界; 以上海流金岁月为设计灵感的顶级娱乐圣殿【红伶】，在华丽典雅的氛围下呈献醉人娱乐表演; 悠然自足以传统手法带领宾客领略养生奥秘恢复活力。从「澳門銀河」穿过设有空调的行人天桥，90秒即可直达「澳门百老汇」，零距离体验最地道的澳门特色及亚洲魅力。百老汇美食街搜罗了35种澳门及亚洲地道特色美食，从街头小吃至老字号餐厅，每家店的招牌名菜都令人难忘。设有约2,500个座位的百老汇舞台汇聚世界级表演盛事。

「澳門銀河」备有独特完善的活动场地，专业的服务团队为宾客筹办不同类型的会议展览活动。银河国际会议中心（ GICC ）将为澳门会展业开启新篇章，同时拓展集团在澳门的度假城版图。其会展空间总面积达40,000平方米，并设有16,000座位、全澳最大的室内综艺馆——银河综艺馆。

详情请浏览：www.galaxyresorts.com.cn, www.broadwaymacau.com.mo及www.galaxyicc.com。